Generics in Scandinavia - Market Summary, Competitive Analysis and Forecast to 2025
Generics in Scandinavia - Market @Summary, Competitive Analysis and Forecast to 2025
SUMMARY
Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Scandinavian generics market had total revenues of $2.8bn in 2020, representing a compound annual growth rate (CAGR) of 3.7% between 2016 and 2020.
- Market consumption volume increased with a CAGR of 3.1% between 2016 and 2020, to reach a total of 58.7% in 2020.
- The four Scandinavian countries are heavily driven by a large government public health market and they have been affected by the trend of western governments cutting down on pharmaceutical spending, instead trying to encourage the greater adoption of generics and cheaper alternatives.
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Scandinavia
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia generics market with five year forecasts
- What was the size of the Scandinavia generics market by value in 2020?
- What will be the size of the Scandinavia generics market in 2025?
- What factors are affecting the strength of competition in the Scandinavia generics market?
- How has the market performed over the last five years?
- What are the main segments that make up Scandinavia's generics market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
8.4. Sanofi SA
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
8.4. Sanofi SA
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Scandinavia generics market value: $ million, 2016-20
Table 2: Scandinavia generics market volume: %, 2016-20
Table 3: Scandinavia generics market geography segmentation: $ million, 2020
Table 4: Scandinavia generics market value forecast: $ million, 2020-25
Table 5: Scandinavia generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: Sanofi SA: key facts
Table 17: Sanofi SA: Annual Financial Ratios
Table 18: Sanofi SA: Key Employees
Table 19: Sanofi SA: Key Employees Continued
Table 20: Scandinavia exchange rate, 2016-20
Table 1: Scandinavia generics market value: $ million, 2016-20
Table 2: Scandinavia generics market volume: %, 2016-20
Table 3: Scandinavia generics market geography segmentation: $ million, 2020
Table 4: Scandinavia generics market value forecast: $ million, 2020-25
Table 5: Scandinavia generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: Sanofi SA: key facts
Table 17: Sanofi SA: Annual Financial Ratios
Table 18: Sanofi SA: Key Employees
Table 19: Sanofi SA: Key Employees Continued
Table 20: Scandinavia exchange rate, 2016-20
LIST OF FIGURES
Figure 1: Scandinavia generics market value: $ million, 2016-20
Figure 2: Scandinavia generics market volume: %, 2016-20
Figure 3: Scandinavia generics market geography segmentation: % share, by value, 2020
Figure 4: Scandinavia generics market value forecast: $ million, 2020-25
Figure 5: Scandinavia generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in Scandinavia, 2020
Figure 7: Drivers of buyer power in the generics market in Scandinavia, 2020
Figure 8: Drivers of supplier power in the generics market in Scandinavia, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2020
Figure 11: Drivers of degree of rivalry in the generics market in Scandinavia, 2020
Figure 1: Scandinavia generics market value: $ million, 2016-20
Figure 2: Scandinavia generics market volume: %, 2016-20
Figure 3: Scandinavia generics market geography segmentation: % share, by value, 2020
Figure 4: Scandinavia generics market value forecast: $ million, 2020-25
Figure 5: Scandinavia generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in Scandinavia, 2020
Figure 7: Drivers of buyer power in the generics market in Scandinavia, 2020
Figure 8: Drivers of supplier power in the generics market in Scandinavia, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2020
Figure 11: Drivers of degree of rivalry in the generics market in Scandinavia, 2020
